— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03, 2018 (GLOBE ...
(Reuters) - U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback